We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

93 hedge funds and large institutions have $404M invested in Lyell Immunopharma in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

586% more call options, than puts

Call options by funds: $48K | Put options by funds: $7K

83% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 18

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0.07% more ownership

Funds ownership: 2.27% → 2.34% (+0.07%)

0% more funds holding

Funds holding: 93 → 93 (0)

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

51% less capital invested

Capital invested by funds: $823M → $404M (-$419M)

Holders
93
Holders Change
–
Holders Change %
0%
% of All Funds
1.49%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
15
Increased
33
Reduced
18
Closed
14
Calls
$48K
Puts
$7K
Net Calls
+$41K
Net Calls Change
+$26K

Top Buyers

1
State Street
State Street
Massachusetts
+$16.7M
2
Goldman Sachs
Goldman Sachs
New York
+$4.11M
3
BlackRock
BlackRock
New York
+$2.19M
4
Bank of America
Bank of America
North Carolina
+$1.95M
5
UBS Group
UBS Group
Switzerland
+$1.94M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.61M
3
Invesco
Invesco
Georgia
-$1.27M
4
KHCM
Kettle Hill Capital Management
New York
-$1.16M
5
Morgan Stanley
Morgan Stanley
New York
-$974K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$193K -$1.27M -12,766 -82%
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
$192K -$327K -3,295 -54%
EAM
53
Erste Asset Management
Austria
$178K – – –
Principal Financial Group
54
Principal Financial Group
Iowa
$170K +$15.7K +158 +7%
ProShare Advisors
55
ProShare Advisors
Maryland
$149K +$14.7K +148 +7%
American Century Companies
56
American Century Companies
Missouri
$138K +$67K +675 +52%
VEA
57
Virtus ETF Advisers
New York
$137K +$80.6K +811 +70%
State Board of Administration of Florida Retirement System
58
State Board of Administration of Florida Retirement System
Florida
$112K +$18.4K +185 +13%
EFM
59
E Fund Management
China
$105K +$79.4K +799 +113%
AGM
60
Alpine Global Management
New York
$94K +$134K +1,353 New
Envestnet Asset Management
61
Envestnet Asset Management
Illinois
$80.8K -$397 -4 -0.3%
Walleye Trading
62
Walleye Trading
New York
$78.3K -$94K -946 -46%
AB
63
Amalgamated Bank
New York
$77K – – –
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$74K +$96.5K +971 +925%
WP
65
Woodline Partners
California
$72K – – –
Citadel Advisors
66
Citadel Advisors
Florida
$59.2K +$84.8K +854 New
CGL
67
Clarius Group LLC
Washington
$57K – – –
GCP
68
GSA Capital Partners
United Kingdom
$56K +$79.9K +804 New
Legal & General Group
69
Legal & General Group
United Kingdom
$55.8K – – –
XT
70
XTX Topco
Cayman Islands
$54.2K +$77.6K +781 New
AP
71
Adero Partners
California
$45.3K – – –
Prudential Financial
72
Prudential Financial
New Jersey
$43.6K +$397 +4 +0.6%
Mackenzie Financial
73
Mackenzie Financial
Ontario, Canada
$38.9K – – –
AIP
74
Ameritas Investment Partners
Nebraska
$38.7K – – –
ZIM
75
Zacks Investment Management
Illinois
$37.6K +$53.8K +542 New
1 2
3
4 5

LYEL Hedge Fund Activity: Q4 2022 in Review

93 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2022, worth a combined $404M — down 51% from $823M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LYEL positions and 14 closed out — a net gain of 1 holder — while 33 added to existing stakes and 18 trimmed.

The largest buyer was State Street, adding an estimated $16.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.1M.

  • 93 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $404M of Lyell Immunopharma stock for Q4 2022, down 51% quarter-over-quarter.
  • 15 funds opened new Lyell Immunopharma positions in Q4 2022 and 14 closed out, a net change of +1 holder.
  • The largest Lyell Immunopharma buyer in Q4 2022 was State Street, an estimated $16.7M added.
  • The largest Lyell Immunopharma seller in Q4 2022 was T. Rowe Price Associates, an estimated $8.1M sold.

Based on aggregated 13F filings for Q4 2022.